{"entity":{"id":"nct05128487","kind":"trial","name":"A Study of NDI 1150-101 in Patients With Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Pembrolizumab in renal cell carcinoma and non-small-cell lung cancer, run by Nimbus Saturn, Inc., active and no longer recruiting.","summary":"A Study of NDI 1150-101 in Patients With Solid Tumors is a phase 1/2 interventional study registered as NCT05128487 by Nimbus Saturn, Inc., with 106 participants planned, started 2021-11-05 and due to reach its primary completion in 2025-02. Interventions recorded: NDI-101150, Pembrolizumab. Conditions listed: Solid Tumor, Renal Cell Carcinoma (Kidney Cancer), Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma, Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05128487","url":"https://clinicaltrials.gov/study/NCT05128487"}],"tags":["ctgov-ingest"],"related":[],"cancers":["rcc","nsclc","sclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["pembrolizumab"],"companies":["nimbus-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct05128487-cell-rep-med-2026"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05128487","phase":"1/2","setting":"A Phase 1/2, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of NDI-101150 Administered as Monotherapy or in Combination With Pembrolizumab in Patients With Solid Tumors","sponsor":"Nimbus Saturn, Inc.","started":"2021-11-05","startedType":"actual","enrolled":106,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05128487/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"nimbus-therapeutics","kind":"company","name":"Nimbus Therapeutics","route":"/companies/nimbus-therapeutics/"}],"paper":[{"id":"paper-nct05128487-cell-rep-med-2026","kind":"paper","name":"HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results","route":"/key-papers/paper-nct05128487-cell-rep-med-2026/"}]}}